Evidence map›Paper›PMID 24366071›Full record

ReviewNature reviews. Cardiology2014

Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics.

Dimitri P Mikhailidis, Vasilios G Athyros

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.Medical science monitor : international medical journal of experimental and clinical research · 2015
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Dimitri P MikhailidisDepartment of Clinical Biochemistry (Vascular Prevention Clinic), Royal Free Hospital Campus, University College School of Medicine, Pond Street, London NW3 2QG, UK.
Vasilios G AthyrosAtherosclerosis and Metabolic Syndrome Outpatient Units, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, 15 Marmara Street, 55132 Thessaloniki, Greece.
Aristotle University of Thessaloniki · GRUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The new ACC/AHA guidelines on treatment of blood cholesterol focus on intensity of statin therapy rather than target levels of lipids. Early studies show substantial reductions in LDL-cholesterol level with antibodies against PCSK9. MicroRNA silencing and gene-repair techniques to treat dyslipidaemia are promising strategies under development.

Indexed as

Practice Guidelines as TopicDyslipidemiasHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLipidsRetrospective StudiesHydroxymethylglutaryl-CoA Reductase InhibitorsLipids

Identifiers

PMID24366071
OpenAlexW2013733939

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.